

# Marcus Pickhardt

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11504134/publications.pdf>

Version: 2024-02-01

26  
papers

2,720  
citations

331670

21  
h-index

454955

30  
g-index

30  
all docs

30  
docs citations

30  
times ranked

3138  
citing authors

#	ARTICLE	IF	CITATIONS
1	“Lest we forget you” methylene blue   Neurobiology of Aging, 2011, 32, 2325.e7-2325.e16.	3.1	316
2	Anthraquinones Inhibit Tau Aggregation and Dissolve Alzheimer's Paired Helical Filaments in Vitro and in Cells. Journal of Biological Chemistry, 2005, 280, 3628-3635.	3.4	305
3	Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy. Journal of Biological Chemistry, 2006, 281, 1205-1214.	3.4	302
4	Development of Tau Aggregation Inhibitors for Alzheimer's Disease. Angewandte Chemie - International Edition, 2009, 48, 1740-1752.	13.8	249
5	Tau protein and tau aggregation inhibitors. Neuropharmacology, 2010, 59, 276-289.	4.1	162
6	Rhodanine-Based Tau Aggregation Inhibitors in Cell Models of Tauopathy. Angewandte Chemie - International Edition, 2007, 46, 9215-9219.	13.8	145
7	Curcumin-Derived Pyrazoles and Isoxazoles: Swiss Army Knives or Blunt Tools for Alzheimer's Disease?. ChemMedChem, 2008, 3, 165-172.	3.2	145
8	The Core of Tau-Paired Helical Filaments Studied by Scanning Transmission Electron Microscopy and Limited Proteolysis. Biochemistry, 2006, 45, 6446-6457.	2.5	130
9	Phenylthiazolyl-Hydrazide and Its Derivatives Are Potent Inhibitors of $\tau$ , Aggregation and Toxicity in Vitro and in Cells. Biochemistry, 2007, 46, 10016-10023.	2.5	129
10	Mechanistic Basis of Phenothiazine-Driven Inhibition of Tau Aggregation. Angewandte Chemie - International Edition, 2013, 52, 3511-3515.	13.8	127
11	Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease. Journal of Medicinal Chemistry, 2013, 56, 4135-4155.	6.4	105
12	Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human Tau. Acta Neuropathologica Communications, 2015, 3, 25.	5.2	102
13	Screening for Inhibitors of Tau Polymerization. Current Alzheimer Research, 2005, 2, 219-226.	1.4	81
14	Inhibition of Tau Filament Formation by Conformational Modulation. Journal of the American Chemical Society, 2013, 135, 2853-2862.	13.7	65
15	Screening for Inhibitors of Tau Protein Aggregation into Alzheimer Paired Helical Filaments: A Ligand Based Approach Results in Successful Scaffold Hopping. Current Alzheimer Research, 2007, 4, 315-323.	1.4	57
16	Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies. Current Alzheimer Research, 2015, 12, 814-828.	1.4	53
17	Inhibition of Tau Aggregation in Cell Models of Tauopathy. Current Alzheimer Research, 2007, 4, 544-546.	1.4	34
18	Selection and Characterization of Tau Binding $\alpha$ -Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS ONE, 2016, 11, e0167432.	2.5	32

#	ARTICLE	IF	CITATIONS
19	Nâ€²-Benzylidene-Benzohydrazides as Novel and Selective Tau-PHF Ligands. Journal of Alzheimer's Disease, 2011, 27, 835-843.	2.6	28
20	Structural Basis of Small Molecule Targetability of Monomeric Tau Protein. ACS Chemical Neuroscience, 2018, 9, 2997-3006.	3.5	25
21	Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies. Current Alzheimer Research, 2015, 12, 814-28.	1.4	21
22	Generalizing the Concept of Specific Compound Formulation Additives towards Nonâ€Fluorescent Drugs: A Solubilization Study on Potential Antiâ€Alzheimerâ€Active Smallâ€Molecule Compounds. Angewandte Chemie - International Edition, 2016, 55, 8752-8756.	13.8	19
23	Time course of Tau toxicity and pharmacologic prevention in a cellâ€model of Tauopathy. Neurobiology of Aging, 2017, 57, 47-63.	3.1	19
24	Screening of a neuronal cell model of tau pathology for therapeutic compounds. Neurobiology of Aging, 2019, 76, 24-34.	3.1	12
25	Gaining Insights into Specific Drug Formulation Additives for Solubilizing a Potential Antiâ€Alzheimer Disease Drug B4A1. Macromolecular Bioscience, 2017, 17, 1700109.	4.1	6
26	Erweiterung des Konzeptes spezifischer Wirkstoffâ€Formulierungsadditive auf nichtfluoreszierende Wirkstoffe: eine Studie zur Solubilisierung potenzieller Antiâ€Alzheimerâ€Wirkstoffe. Angewandte Chemie, 2016, 128, 8894-8899.	2.0	4